ClinicalTrials.gg
Active, not recruitingNCT03546972Updated Oct 6, 2026

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

An interventional study of Behavioral, Psychological or Informational Intervention and Behavioral, Psychological or Informational Intervention in Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation and Ductal Breast Carcinoma In Situ, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to female participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Enrollment
86th of 171
51 · median 51
Started
2017
with 10 others
No phase
65 of 210
11 open now
Primary completion
2026-11
later than 17 of 50 live
Registered
156th of 210
by date
Lead sponsor
9 of 210
M.D. Anderson Cancer Center

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 86th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 65 with no phase, reaches primary completion later than 17 of the 50 other live ones, and was the 156th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 30 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

This pilot trial studies how well a diabetes prevention program with or without hunger training works in helping to lower breast cancer risk in obese participants. A diabetes prevention program involves learning about and receiving materials on different strategies to encourage weight loss, and hunger training involves learning how to recognize hunger. It is not yet known whether adding hunger training to a diabetes prevention program helps participants control their weight that could reduce the risk of some cancers.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the feasibility of adding hunger training to the Diabetes Prevention Program (DPP) using the following criteria: accrual rates > 50%, attrition rates \< 20% and, in the DPP-plus-hunger training (HT) group, training protocol adherence rates > 75%.

SECONDARY OBJECTIVES:

I. Estimate the magnitude of effect sizes and variation in outcome variables for the DPP-only and DPP-plus-HT interventions on changes in weight; in metabolic and breast cancer risk biomarkers (e.g., fasting insulin and blood glucose [BG] levels, levels of glycosylated hemoglobin, insulin resistance, adiponectin, interleukin-6, and C-reactive protein); and in proposed behavioral mediators (e.g., reduction in total energy intake, overall eating frequency, percent of eating events occurring at or below the average fasting blood BG level).

II. Examine the mediation effects of proposed mechanisms of the interventions related to individual-level behavioral measures of eating self-regulation on the proposed outcomes using a multimodal approach of validated questionnaires and reliable ecological momentary assessment method.

OUTLINE: Participants are randomized to 1 of 2 groups.

GROUP A: Participants take part in DPP once a week over 1 hour for 16 weeks.

GROUP B: Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.

03

Conditions studied

  • Deleterious BRCA1 Gene Mutation
  • Deleterious BRCA2 Gene Mutation
  • Ductal Breast Carcinoma In Situ
  • Obesity
  • Overweight
  • Premalignant Lesion
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) >= 27 kg/m\^2.
  • At high risk of developing breast cancer defined by one or more of the following: Gail model lifetime risk > 20% or a 5 year risk >1.66%, a history of deleterious BRCA1/2 mutation or mantle radiation, a history of ductal cancer in situ, or a history of high risk premalignant breast lesion.
  • 12 months without a period/menstrual cycle or having had a bilateral oophorectomy.
  • Ability to take digital time stamped photos.
  • Internet access (daily).
  • Reports being proficient in English (can read/write and speak fluently).

Exclusion criteria

Exclusion Criteria:

  • Previous participation in this trial. Participation is defined as screening. Re-screening is not allowed except for individuals excluded for . Patients previous screened as ineligible due to BMI are allowed to be re-screened and enrolled if eligible.
  • Has a current measured BMI less than 27 kg/m\^2.
  • Reports being unwilling to use Continuous Glucose Monitor (CGM), which requires daily blood sampling by finger pricks.
  • Currently being actively treated for cancer other than nonmelanoma skin cancer.
  • Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests.
  • Reported current diagnosis or history of type I diabetes or type 2 diabetes.
  • Reported use of oral antidiabetic agents (OADs).
  • Current use of any drug (except metformin) or anticipated change in concomitant medication, which the investigator's opinion could interfere with the glucose metabolism (e.g. systemic ).
  • Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator).
  • Previous or current treatment with GLP-1 receptor agonists (e.g. exenatide, liraglutide).
  • Fasting blood glucose level > 126 and glycosylated () > 7%.
  • Subjects considered by the investigator as unsuitable for the study for reasons not otherwise stated.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    Group A (DPP)

    Participants take part in DPP once a week over 1 hour for 16 weeks.

    Other: Behavioral, Psychological or Informational Intervention · Other: Questionnaire Administration

  • Experimental
    Group B (DPP-HT)

    Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.

    Other: Behavioral, Psychological or Informational Intervention · Other: Questionnaire Administration

Interventions

  • OtherBehavioral, Psychological or Informational Intervention

    Take part in DDP

  • OtherBehavioral, Psychological or Informational Intervention

    Take part in HT

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by recruitment rate

    Measured by percentage of participants who enroll in the study.

    Time frame: Up to 2 years

  2. Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by drop-out rates

    Measured by percentage of participants who leave the study.

    Time frame: Up to 2 years

  3. Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by completion rates

    Measured by percentage of participants who complete the study.

    Time frame: Up to 2 years

Secondary outcomes

  1. Changes in weight loss

    Will use linear regression to study the effects of participant characteristics (i.e., weight history) and their interactions with the treatment groups.

    Time frame: Baseline to 2 years

  2. Changes in metabolic and breast cancer risk biomarkers

    Biomarkers will be assessed through blood draws.

    Time frame: Baseline to 2 years

  3. Changes in proposed behavioral mediators through survey

    Eating patterns will be assessed through survey ASA24 (Automated Self-assessment).

    Time frame: At baseline and at 16 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Jospe MR, Liao Y, Giles ED, Hudson BI, Slingerland JM, Schembre SM. A low-glucose eating pattern is associated with improvements in glycemic variability among women at risk for postmenopausal breast cancer: an exploratory analysis. Front Nutr. 2024 Apr 10;11:1301427. doi: 10.3389/fnut.2024.1301427. eCollection 2024. PubMed 38660060 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Nov 2026, 107 months after the start.

Of 44 non-industry interventional studies with no phase under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 148. This study's planned 107 months is above that.

Counting every sponsor, half of 47 studies reached it within 69 months; a quarter within 30 and three quarters within 134.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
Jun 6, 2018
StartActual
Dec 17, 2017
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03546972
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
Dec 17, 2017
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Karen M Basen-Engquist
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion